SAFETY & PHARMACOKINETICS OF 552-02 FOLLOWING FOURTEEN DAYS IN CYSTIC FIBROSIS

这个子项目是众多研究子项目之一

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this protocol is to evaluate the safety and tolerability of 552-02 after daily aerosolized administration for fourteen days in patients with cystic fibrosis and to evaluate the plasma pharmacokinetics of 552-02 after daily aerosolized administration for fourteen days in patients with cystic fibrosis. (552-203)